AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease [Yahoo! Finance]
AC Immune SA (ACIU)
Last ac immune sa earnings: 11/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acimmune.com/en/investors
Company Research
Source: Yahoo! Finance
Results show, for the first time, that targeting underlying a-syn pathology with an active immunotherapy could slow the rate of progression of Parkinson's disease Clear safety profile with no clinically relevant safety issues reported Targets met for immunogenicity (100% responder rate), pharmacodynamic effect, target engagement and clinical assessments Underlines potential and importance of active immunotherapies in precision medicine for neurodegenerative diseases AC Immune to host webcast and conference call today at 9:00am ET / 15:00 CET details below Lausanne, Switzerland, December 11, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced positive interim safety and efficacy results from the Phase 2 VacSYn trial of its wholly-owned anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in early Parkinson's disease (PD). The results show, for the first t
Show less
Read more
Impact Snapshot
Event Time:
ACIU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACIU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACIU alerts
High impacting AC Immune SA news events
Weekly update
A roundup of the hottest topics
ACIU
News
- AC Immune posts positive data for Parkinson's immunotherapy [Yahoo! Finance]Yahoo! Finance
- AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s DiseaseGlobeNewswire
- AC Immune to Present at the Jefferies 2025 London Healthcare ConferenceGlobeNewswire
- AC Immune (NASDAQ:ACIU) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $8.00 price target on the stock.MarketBeat
- AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate UpdateGlobeNewswire
ACIU
Earnings
- 11/4/25 - Beat
ACIU
Sec Filings
- 12/11/25 - Form 6-K
- 11/4/25 - Form 6-K
- 10/3/25 - Form 144
- ACIU's page on the SEC website